|
1
|
Wallace DC: Mitochondrial DNA sequence
variation in human evolution and disease. Proc Natl Acad Sci USA.
91:8739–8746. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Liu B, Du Q, Chen L, Fu G, Li S, Fu L,
Zhang X, Ma C and Bin C: CpG methylation patterns of human
mitochondrial DNA. Sci Rep. 6:234212016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Michl L and Shumacher HB Jr: Pulmonary
valvular incompetence in growing animals. Surgery. 73:412–415.
1973.PubMed/NCBI
|
|
4
|
Cavalli LR and Liang BC: Mutagenesis,
tumorigenicity, and apoptosis: Are the mitochondria involved? Mutat
Res. 398:19–26. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Parrella P, Xiao Y, Fliss M,
Sanchez-Cespedes M, Mazzarelli P, Rinaldi M, Nicol T, Gabrielson E,
Cuomo C, Cohen D, et al: Detection of mitochondrial DNA mutations
in primary breast cancer and fine-needle aspirates. Cancer Res.
61:7623–7626. 2001.PubMed/NCBI
|
|
6
|
Hosgood HD III, Liu CS, Rothman N,
Weinstein SJ, Bonner MR, Shen M, Lim U, Virtamo J, Cheng WL,
Albanes D, et al: Mitochondrial DNA copy number and lung cancer
risk in a prospective cohort study. Carcinogenesis. 31:847–849.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jakupciak JP, Maragh S, Markowitz ME,
Greenberg AK, Hoque MO, Maitra A, Barker PE, Wagner PD, Rom WN,
Srivastava S, et al: Performance of mitochondrial DNA mutations
detecting early stage cancer. BMC Cancer. 8:2852008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Galluzzi L, Kepp O and Kroemer G:
Mitochondria: Master regulators of danger signalling. Nat Rev Mol
Cell Biol. 13:780–788. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Goulopoulou S, Matsumoto T, Bomfim GF and
Webb RC: Toll-like receptor 9 activation: A novel mechanism linking
placenta-derived mitochondrial DNA and vascular dysfunction in
pre-eclampsia. Clin Sci. 123:429–435. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Underhill DM, Ozinsky A, Smith KD and
Aderem A: Toll-like receptor-2 mediates mycobacteria-induced
proinflammatory signaling in macrophages. Proc Natl Acad Sci USA.
96:14459–14463. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Latz E, Visintin A, Espevik T and
Golenbock DT: Mechanisms of TLR9 activation. J Endotoxin Res.
10:406–412. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Nishiya T, Kajita E, Miwa S and Defranco
AL: TLR3 and TLR7 are targeted to the same intracellular
compartments by distinct regulatory elements. J Biol Chem.
280:37107–37117. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang Q, Raoof M, Chen Y, Sumi Y, Sursal
T, Junger W, Brohi K, Itagaki K and Hauser CJ: Circulating
mitochondrial DAMPs cause inflammatory responses to injury. Nature.
464:104–107. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hemmi H, Takeuchi O, Kawai T, Kaisho T,
Sato S, Sanjo H, Matsumoto M, Hoshino K, Wagner H, Takeda K, et al:
A Toll-like receptor recognizes bacterial DNA. Nature. 408:740–745.
2000. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Latz E, Schoenemeyer A, Visintin A,
Fitzgerald KA, Monks BG, Knetter CF, Lien E, Nilsen NJ, Espevik T
and Golenbock DT: TLR9 signals after translocating from the ER to
CpG DNA in the lysosome. Nat Immunol. 5:190–198. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Akira S and Hoshino K: Myeloid
differentiation factor 88-dependent and -independent pathways in
toll-like receptor signaling. J Infect Dis. 187 Suppl 2:S356–S363.
2003. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Vollmer J: TLR9 in health and disease. Int
Rev Immunol. 25:155–181. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Berger R, Fiegl H, Goebel G, Obexer P,
Ausserlechner M, Doppler W, Hauser-Kronberger C, Reitsamer R, Egle
D, Reimer D, et al: Toll-like receptor 9 expression in breast and
ovarian cancer is associated with poorly differentiated tumors.
Cancer Sci. 101:1059–1066. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Väisänen MR, Väisänen T, Jukkola-Vuorinen
A, Vuopala KS, Desmond R, Selander KS and Vaarala MH: Expression of
toll-like receptor-9 is increased in poorly differentiated prostate
tumors. Prostate. 70:817–824. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kauppila JH, Takala H, Selander KS,
Lehenkari PP, Saarnio J and Karttunen TJ: Increased Toll-like
receptor 9 expression indicates adverse prognosis in oesophageal
adenocarcinoma. Histopathology. 59:643–649. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sandholm J and Selander KS: Toll-like
receptor 9 in breast cancer. Front Immunol. 5:3302014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Krieg AM: Toll-like receptor 9 (TLR9)
agonists in the treatment of cancer. Oncogene. 27:161–167. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wooldridge JE and Weiner GJ: CpG DNA and
cancer immunotherapy: Orchestrating the antitumor immune response.
Curr Opin Oncol. 15:440–445. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2ΔΔCT method. Methods.
25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lo YM, Tein MS, Lau TK, Haines CJ, Leung
TN, Poon PM, Wainscoat JS, Johnson PJ, Chang AM and Hjelm NM:
Quantitative analysis of fetal DNA in maternal plasma and serum:
Implications for noninvasive prenatal diagnosis. Am J Hum Genet.
62:768–775. 1998. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
Vecchiarelli A, Retini C, Casadevall A,
Monari C, Pietrella D and Kozel TR: Involvement of C3a and C5a in
interleukin-8 secretion by human polymorphonuclear cells in
response to capsular material of Cryptococcus neoformans. Infect
Immun. 66:4324–4330. 1998.PubMed/NCBI
|
|
27
|
Waugh DJ and Wilson C: The interleukin-8
pathway in cancer. Clin Cancer Res. 14:6735–6741. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Arango Duque G and Descoteaux A:
Macrophage cytokines: Involvement in immunity and infectious
diseases. Front Immunol. 5:4912014.PubMed/NCBI
|
|
29
|
Aldinucci D and Colombatti A: The
inflammatory chemokine CCL5 and cancer progression. Mediators
Inflamm. 2014:2923762014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lee MS, Kim HP, Kim TY and Lee JW:
Gefitinib resistance of cancer cells correlated with
TM4SF5-mediated epithelial-mesenchymal transition. Biochim Biophys
Acta. 1823:514–523. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lee H, Lee JH, Kim DC, Hwang I, Kang YN,
Gwon GJ, Choi IJ and Kim S: Is mitochondrial DNA copy number
associated with clinical characteristics and prognosis in gastric
cancer? Asian Pac J Cancer Prev. 16:87–90. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Qu F, Chen Y, Wang X, He X, Ren T, Huang
Q, Zhang J, Liu X, Guo X, Gu J and Xing J: Leukocyte mitochondrial
DNA content: A novel biomarker associated with prognosis and
therapeutic outcome in colorectal cancer. Carcinogenesis.
36:543–552. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Weerts MJ, Sieuwerts AM, Smid M, Look MP,
Foekens JA, Sleijfer S and Martens JW: Mitochondrial DNA content in
breast cancer: Impact on in vitro and in vivo phenotype and patient
prognosis. Oncotarget. 7:29166–29176. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Pao W and Chmielecki J: Rational,
biologically based treatment of EGFR-mutant non-small-cell
lung cancer. Nat Rev Cancer. 10:760–774. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Liu B, Su Y, Li T, Yuan W, Mo X, Li H, He
Q, Ma D and Han W: CMTM7 knockdown increases tumorigenicity of
human non-small cell lung cancer cells and EGFR-AKT signaling by
reducing Rab5 activation. Oncotarget. 6:41092–41107. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Droemann D, Albrecht D, Gerdes J, Ulmer
AJ, Branscheid D, Vollmer E, Dalhoff K, Zabel P and Goldmann T:
Human lung cancer cells express functionally active Toll-like
receptor 9. Respir Res. 6:12005. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Damiano V, Caputo R, Bianco R, D'Armiento
FP, Leonardi A, De Placido S, Bianco AR, Agrawal S, Ciardiello F
and Tortora G: Novel toll-like receptor 9 agonist induces epidermal
growth factor receptor (EGFR) inhibition and synergistic antitumor
activity with EGFR inhibitors. Clin Cancer Res. 12:577–583. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Han R, Wang X, Zhong D, Zhao J, Chen Z,
Sun L, Wang J and Zhang J: Molecular mechanism of erlotinib
resistance in epidermal growth factor receptor mutant non-small
cell lung cancer cell line H1650. Zhongguo Fei Ai Za Zhi.
15:689–693. 2012.(In Chinese). PubMed/NCBI
|
